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Abstract: Chronic infection with the hepatitis C virus (HCV) affects
170 million people worldwide and is an important cause of liver-
related morbidity and mortality. The standard of care therapy com-
bines pegylated interferon (peg-IFN) alpha and ribavirin (RBV), and
is associated with a range of treatment-limiting adverse effects.
One of the most important of these is RBV-induced haemolytic anae-
mia, which affects most patients and is severe enough to require dose
modiﬁcation in up to 15% of the patients. Here we show that genetic
variants leading to inosine triphosphatase deﬁciency, a condition not
thought to be clinically important, protect against haemolytic anae-
mia in hepatitis C-infected patients receiving RBV.
 2010 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.
Hepatitis C virus (HCV) is a major cause of chronic liver dis-
ease worldwide. In addition to the viral and environmental
behavioural factors, host genetic diversity is believed to contrib-
ute to the spectrum of the disease [1]. The standard of care (SOC)
consists of the combination of pegylated interferon (Peg-IFN)
plus ribavirin (RBV). However, this care only induces a sustained
virological response (SVR) in half of genotype 1 patients. Several
independent genome wide association studies (GWAS)s reported
single nucleotide polymorphisms (SNP)s in the IL28B (IFN-k3)
region, associated with SVR [2,3]. The mechanisms by which
RBV enhances the rate of SVR when added to IFNs remain
unknown. Chances to achieve an SVR signiﬁcantly decrease when
the patients receive less than 80% of the total dose of peg-IFN
and/or less than 80% of the total RBV and/or during less than
80% of the total treatment duration [4].
The current SOC causes a mean decline in haemoglobin (Hb)
concentrations of approximately 3 g/dl. The RBV-induced anae-
mia most often occurs as a dose-dependent haemolytic anaemia,
typically developing within the ﬁrst 4 weeks of therapy [5]. IFN
can also contribute to the development of anaemia by suppressingJournal of Hepatology 20
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induced anaemia, but the discontinuation of RBV is sometimes
necessary. The conventional SOC for managing anaemia during
the therapy has consisted in reducing the RBV dose if the haemo-
globin level decreases to less than 10 g/dl, and to completely stop
it if the haemoglobin level drops below 8.5 g/dl. A decrease in the
RBV dose, especially in the ﬁrst several months of treatment, can
diminish the response rates considerably. The recombinant eryth-
ropoietin hormone, epoetin alfa (Epogen, Procrit), has emerged as
an option for improving HCV treatment-related anaemia while
supporting the optimal treatment doses of RBV and IFN. No study,
however, has established that the use of erythropoietin increases
the overall SVR rates associated with HCV therapy [5]. Interest-
ingly, viramidine (currently known as taribavirin), a prodrug of
RBV taken up predominantly by hepatocytes and extensively con-
verted to RBV by adenosine deaminase has been developed [6]. It
is known that viramidine does not accumulate in red blood cells,
so this agent is likely to be associated with lower anaemia rates.
Compared to ribavirine, viramidine did not meet the primary efﬁ-
cacy non-inferiority end-point but met the safety end-point [6].
Determination of a viramidine dosage that would yield superior
efﬁcacy over RBV is needed.
RBV is essential for improving SVR through preventing
relapses and a breakthrough. Bronowicki et al. investigated the
consequence of RBV cessation in genotype 1-infected patients
who cleared HCV RNA at week 24 [7]. They randomised patients
to either combination therapy after 24 weeks or Peg-IFN alpha-2a
alone. Patients who stopped RBV had signiﬁcantly higher viral
breakthroughs and SVR was reduced. However, stopping RBV at
24 weeks in patients who had experienced a rapid virologic
response did not affect SVR. Similar data were also generated
by the IDEAL study, which compared SVR amonst three
groups: (i) Peg-IFN alpha-2b 1.5 g/kg/week + RBV 800–1400 mg/
day; (ii) Peg-IFN alpha-2b 1.0 g/kg/week + RBV 800–1400 mg/
day; and (iii) peginterferon-alpha-2a 180 g/kg/week + RBV
1000–1200 mg/day [8]. Increased exposure to RBV was associ-
ated with an increased SVR. Although anaemia requiring dose
reduction and/or erythropoietin occurred in 28% of all patients,
this did not reduce the SVR. In fact, patients with anaemia need-
ing RBV dose reduction had a higher rate of SVR even when the
RBV was reduced by as much as 50%. Anaemia is linked to RBV
concentration, even if this relationship is highly variable. To opti-
mise RBV utilisation, it has been proposed that the global expo-
sure after the ﬁrst dose of ribavirin is an early and robust
pharmacokinetic predictor of SVR [9].10 vol. 53 j 971–973
Fig. 1. ITPA deﬁciency protects against clinically signiﬁcant RBV-induced decline in Hb concentration. Adapted from Felay et al. [10]. Percentages of clinically signiﬁcant
anaemia at week 4 (deﬁned as either a decline in Hb of >3 g/dl and/or Hb levels <10 g/dl) are shown according to rs1127354 and rs7270101 combined genotypes.
Rs1127354 and rs7270101 minor variants confer reduced ITPA and induce protection against clinically signiﬁcant haemolytic anaemia in hepatitis C-infected patients
receiving RBV.
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IDEAL study, performed a GWAS of determinants of treatment-
related anaemia in individuals with chronic genotype 1 hepatitis
C [10]. Shortly, GWAS use dense maps of genetic markers that
cover the human genome to look for allele frequency differences
between cases and controls. A signiﬁcant frequency difference
suggests that the corresponding region of the genome contains
functional DNA variants that inﬂuence the trait of interest. The
strength of the genome-wide screening is its ability to reveal
not only genes that would be expected to play a signiﬁcant role,
but also genes that would not, potentially adding a new insight
into physiopathology. A total of 1286 individuals who were clas-
siﬁed into three ethnic groups (988 European–Americans, 198
African–Americans and 100 Hispanics) were available for analy-
ses. Among these 1286 patients, 542 developed clinically signiﬁ-
cant anaemia at week 4 (deﬁned as either a decline in Hb of >3 g/
dl and/or Hb levels <10 g/dl). The primary analysis focused on the
quantitative change in Hb levels from the baseline to the fourth
week of treatment, historically the point at which many patients
begin erythropoietin treatment to stimulate red blood cell pro-
duction. They tested each of 565,759 SNPs passing quality control
measures in a linear regression model incorporating signiﬁcant
clinical covariates including the baseline Hb levels. Several SNPs
on chromosome 20 (20p13 region) were found to be strongly
associated with treatment-induced reduction in Hb at week 4,
with the European–American sample showing overwhelming
genome-wide signiﬁcance (p = 1.1  1045) for an association
between quantitative Hb reduction at week 4 and the SNP
rs6051702.
These SNPs are located in a 250 kb region that contained ﬁve
genes including the inosine triphosphatase (ITPA) gene. The pro-
tein encoded by this gene hydrolyzes inosine triphosphate (ITP)
and deoxyinosine triphosphate (dITP), a central intermediate in
purine metabolism. The encoded protein, which is a member of
the HAM1 NTPase protein family, is found in the cytoplasm and
acts as a homodimer. Defects in the encoded protein can result
in inosine triphosphate pyrophosphorylase deﬁciency [11]. The
putative role of ITPase is to recycle purines trapped in the form972 Journal of Hepatology 201of ITP and to protect cell (including erythrocytes) from the accu-
mulation of nucleotides such ITP, dITP, or xanthosine triphos-
phate (XTP) that may be incorporated into RNA and DNA. ITPA
haplotype structure has shown that the two SNPs rs1127354
(proline-to-threonine substitution) and rs7270101 (splicing
altering SNP) were the most relevant functional variants in deter-
mining ITPA low enzymatic activity and ITP accumulation in red
blood cells [11].
Analysis of HapMap data from European parents found both of
these low-activity variants to be preferentially associated with
the protective rs6051702 C allele. This observation suggested
the possibility that these two known functional ITPA variants
were responsible for the observed association and conferred pro-
tection against anaemia. To test this possibility, Fellay et al.
sequenced the entire coding region of the ITPA gene in a subset
of 168 samples and found no other obvious reduced function
mutations. Moreover, genotyping of the known functional SNPs
rs1127354 and rs7270101 in the entire cohort conﬁrmed that
the two variants co-segregated with the protector rs6051702
minor allele C and entirely explained the association signal ini-
tially identiﬁed in the 20p13 region. These data conﬁrmed that
the two known functional variants conferring reduced ITPA activ-
ity were responsible for the protection against anaemia identiﬁed
in the original GWAS. Moreover, the resulting difference in ITPA
function explained nearly 30% of the variability in quantitative
Hb reduction in the European–American sample.
Fellay et al. also demonstrated that their observation had clin-
ical relevance as ITPA deﬁciency was found to protect against
clinically signiﬁcant anaemia deﬁned as either a decline in Hb
of >3 g/dl or Hb levels <10 g/dl at week 4, which is the threshold
at which RBV dose reduction is recommended (Fig. 1). However,
no signiﬁcant association has been observed between the ITPA
deﬁciency variants and early or late anti-HCV treatment
outcomes.
A proposed model to explain these observations would be that
the accumulation of ITP caused by ITPA deﬁciency competes with
the triphosphate active form of ribavirin (RBV-TP) in unknown
cellular processes, and thereby protects cells from the lytic effects0 vol. 53 j 971–973
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of RBV-TP that also accumulates in red blood cells. However, the
mechanism of RBV-induced haemolytic anaemia and the herein
described protective effect of ITPA deﬁciency remains to be
clearly understood. Because ITPA deﬁciency seems to be a benign
condition, therapies that target this enzyme could help protect
against RBV-induced anaemia and testing patients for the deﬁ-
ciency could help identify those at risk.
This study by Fellay et al. constitutes a clear example of a
synthetic association in which the effects of rarer functional
variants are observed as an association for a more common var-
iant present on a whole genome genotyping chip. Relatively
common genetic variants have been identiﬁed by GWAS that
explain very signiﬁcant proportions of the population variation
in drug responses, including the ITPA variants described here
and the IL28B variants reported recently [2,3]. It is also worth
noting that four GWAS have recently reported associations with
a range of clinically relevant haematological traits [12]. These
studies notably identiﬁed several SNPs in the hexokinase 1 gene
(HK1 on chromosome 10) signiﬁcantly associated with two
erythrocyte traits (Hb concentration and haematocrit). Interest-
ingly, HK1 SNPs were also identiﬁed by Fellay et al. in the con-
text of RBV-induced anaemia, although the association did not
reach GWAS signiﬁcance [10]. The study by Fellay et al. repre-
sents important additional progress in identifying candidate
genes associated with diverse and clinically relevant blood-cell
traits. The identiﬁcation of ITPA deﬁciency as a major protective
factor against RBV-induced haemolytic anaemia not only pro-
vides a valuable pharmacogenetic diagnostic and maybe phar-
macological target, but also provides new insights into red
blood cell biology.
Prediction of ribavirin-induced anaemia is an important
issue. Protease inhibitors are designed for genotype 1 and there-
fore will be ﬁrst registered to be associated with PEG-IFN and
ribavirin for genotype 1 infected patients [13]. Ribavirin is a
drug which is essential to produce higher SVR rates both with
Peg-IFN and HCV protease inhibitors currently in Phase III clin-
ical trials. For other genotypes (2, 3 and 4), the SOC (PEG-IFN
plus ribavirin) will be used for several years. Thus, ribavirin will
stay an important drug to achieve higher SVR rates in HCVJournal of Hepatology 201infected persons, and the prediction of anaemia will remain
an important issue.Conﬂict of interest
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